Position in EXEL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$63,086,055
-$69,985,917 QoQ
Shares Held
1,159,457
-62.6% QoQ
Ownership
0.468%
of shares outstanding
% of Portfolio
0.23%
of 13F equity value
Holder Rank
#40
of 739 holders
Holding Since
Mar 2020
21 quarters on record
Voting authority
Sole 76%
Shared 0%
None 24%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names. EXEL ranks #6 (7.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
729,635 | $219,642,024 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
1,938,035 | $151,689,999 | |
| 3 | CAI |
Caris Life Sciences, Inc.
|
3,958,531 | $70,541,022 | |
| 4 | INCY |
Incyte Corp
|
578,986 | $65,633,852 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
130,802 | $64,973,277 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
1,159,457 | $63,086,055 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
98,585 | $61,471,690 | |
| 8 | RPRX |
Royalty Pharma plc
|
877,674 | $49,211,181 |
All Filings in EXEL
Export CSV
21 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $63,086,055 | 1,159,457 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $133,071,972 | 3,102,634 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $49,572,518 | 1,131,018 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $40,809,851 | 988,132 | Shares | Sole | 2025-10-20 | |
| 2025-06-30 | $54,224,615 | 1,230,141 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $32,216,576 | 872,605 | Shares | Sole | 2025-05-05 | |
| 2024-12-31 | $71,827,966 | 2,156,996 | Shares | Sole | 2025-02-04 | |
| 2024-09-30 | $46,472,687 | 1,790,855 | Shares | Sole | 2024-11-04 | |
| 2024-06-30 | $17,961,641 | 799,361 | Shares | Sole | 2024-08-05 | |
| 2024-03-31 | $58,239,993 | 2,454,277 | Shares | Sole | 2024-04-05 | |
| 2023-12-31 | $5,616,706 | 234,127 | Shares | Sole | 2024-02-06 | |
| 2023-09-30 | $5,342,040 | 244,487 | Shares | Sole | 2023-11-06 | |
| 2023-06-30 | $17,724,505 | 927,499 | Shares | Sole | 2023-08-03 | |
| 2023-03-31 | $29,038,990 | 1,496,084 | Shares | Sole | 2023-05-04 | |
| 2022-12-31 | $33,036,593 | 2,059,638 | Shares | Sole | 2023-02-06 | |
| 2022-09-30 | $27,392,818 | 1,746,991 | Shares | Sole | 2022-11-02 | |
| 2021-03-31 | $716,193 | 31,704 | Shares | Sole | 2021-05-05 | |
| 2020-12-31 | $2,456,066 | 122,375 | Shares | Sole | 2021-03-10 | |
| 2020-09-30 | $2,991,702 | 122,360 | Shares | Sole | 2020-11-02 | |
| 2020-06-30 | $13,683,403 | 576,386 | Shares | Sole | 2020-08-05 | |
| 2020-03-31 | $231,746 | 13,458 | Shares | Sole | 2020-05-04 | |
| No filing history on record for this holder in this stock. | ||||||